Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Henlius Biotech, Inc. has announced that the first patient has been dosed in a Phase 2 clinical trial in mainland China, testing a combination of its drugs HLX53, HANSIZHUANG, and HANBEITAI for the treatment of advanced liver cancer. This trial aims to assess the safety, efficacy, and tolerability of the drug combination compared to a placebo in patients with untreated hepatocellular carcinoma. The company’s innovative anti-TIGIT Fc fusion protein HLX53, anti-PD-1 monoclonal antibody HANSIZHUANG, and bevacizumab biosimilar HANBEITAI highlight their expanding portfolio in cancer therapies.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.